Literature DB >> 10804016

Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats.

A Haffa1, D Krueger, J Bruner, J Engelke, C Gundberg, M Akhter, N Binkley.   

Abstract

To further characterize the skeletal role of vitamin K (K), markers of bone turnover, density, and strength were evaluated in rats with diet- or warfarin (W)-induced K insufficiency. One hundred two, 7-week-old, female rats were randomly assigned to low K (phylloquinone [K1], 20 microg/kg diet), control K (K1, 1300 microg/kg diet), low-dose W (W, 1.5 mg/kg control diet), or high-dose W plus K (W/K1, 10/100 mg/kg diet). Femur bone mineral content (BMC) and bone mineral density (BMD), plasma prothrombin time (PT) and prothrombin concentration (PC), and serum total alkaline phosphatase (ALP) and skeletal alkaline phosphatase (sALP) were measured at baseline and days 20, 40, 60, and 80. Serum total osteocalcin (OC) and undercarboxylated osteocalcin (ucOC) and femur length (FL) were measured at baseline and day 80. Left femur OC was measured and biomechanical testing of the right femur and third lumbar vertebral body was performed at day 80. Low dietary K elevated circulating ucOC (17% higher than control; p < 0.0001) at day 80. Furthermore, in both W groups, essentially all circulating OC was undercarboxylated and femur OC was lower than control (p < 0.0001). However, there was no change in femur percent ucOC, suggesting deposition of less newly synthesized OC. No between group differences were observed in PT, ALP, sALP, FL, BMC, BMD, or bone strength. In conclusion, skeletal K insufficiency can be induced by W or diet manipulation. This does not hinder peak bone mass attainment in female rats; however, W causes less newly synthesized OC to be deposited in bone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804016     DOI: 10.1359/jbmr.2000.15.5.872

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

Review 1.  Bone as an endocrine organ relevant to diabetes.

Authors:  Sarah L Booth; Amanda J Centi; Caren Gundberg
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

Review 2.  Bone and glucose metabolism: a two-way street.

Authors:  Katherine J Motyl; Laura R McCabe; Ann V Schwartz
Journal:  Arch Biochem Biophys       Date:  2010-08-01       Impact factor: 4.013

3.  Comparison of inhibitory effects of warfarin on gamma-carboxylation between bone and liver in rats.

Authors:  Kuniko Hara; Masatoshi Kobayashi; Yasuhiro Akiyama
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

4.  Measurement of bioactive osteocalcin in humans using a novel immunoassay reveals association with glucose metabolism and β-cell function.

Authors:  Julie Lacombe; Omar Al Rifai; Lorraine Loter; Thomas Moran; Anne-Frédérique Turcotte; Thomas Grenier-Larouche; André Tchernof; Laurent Biertho; André C Carpentier; Denis Prud'homme; Rémi Rabasa-Lhoret; Gerard Karsenty; Claudia Gagnon; Weiping Jiang; Mathieu Ferron
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-01-14       Impact factor: 4.310

5.  Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis.

Authors:  Elvy Suhana Mohd Ramli; Farihah Suhaimi; Siti Fadziyah Mohamad Asri; Fairus Ahmad; Ima Nirwana Soelaiman
Journal:  J Bone Miner Metab       Date:  2012-12-30       Impact factor: 2.626

6.  Vitamin E exhibits bone anabolic actions in normal male rats.

Authors:  Ahmad Nazrun Shuid; Zulfadli Mehat; Norazlina Mohamed; Norliza Muhammad; Ima Nirwana Soelaiman
Journal:  J Bone Miner Metab       Date:  2009-09-25       Impact factor: 2.626

7.  Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice.

Authors:  V E DeMambro; D R Clemmons; L G Horton; M L Bouxsein; T L Wood; W G Beamer; E Canalis; C J Rosen
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

8.  2MD, a new anabolic agent for osteoporosis treatment.

Authors:  L A Plum; L A Fitzpatrick; X Ma; N C Binkley; J B Zella; M Clagett-Dame; H F DeLuca
Journal:  Osteoporos Int       Date:  2006-02-21       Impact factor: 4.507

9.  Establishing a rat model for the study of vitamin K deficiency.

Authors:  Yanni Mi; Xue Xiao; Dongzheng Liu; Nana Ping; Yanbing Zhu; Bo Li; Lihui Long; Yongxiao Cao
Journal:  Int J Exp Pathol       Date:  2016-06-03       Impact factor: 1.925

10.  Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women.

Authors:  Neil Binkley; Judith Harke; Diane Krueger; Jean Engelke; Nellie Vallarta-Ast; Dessa Gemar; Mary Checovich; Richard Chappell; John Suttie
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.